Inflammation and Coagulation in Neurologic and Psychiatric Disorders

Abstract

Coagulation factors are intrinsically expressed in various brain cells, including astrocytes and microglia. Their interaction with the inflammatory system is important for the well-being of the brain, but they are also crucial in the development of many diseases in the brain such as stroke and traumatic brain injury. The cellular effects of coagulation are mediated mainly by protease-activated receptors. In this review, we sum up the role of the coagulation cascade in the development of different diseases including psychiatric disorders. In inflammatory diseases such as multiple sclerosis, fibrinogen activates microglia and suppresses the differentiation of oligodendrocytes, leading to axonal damage and suppression of remyelination. In ischemic stroke, thrombin activity is associated with the size of infarction, and the inhibition of either thrombin- or protease-activated receptor 1 promotes neuronal survival and reduces the size of infarction. Patients suffering from Alzheimer's disease express higher levels of thrombin, which in turn damages the endothelium, increases blood–brain barrier permeability, and induces cell apoptosis. In major depressive disorder, a positive correlation is present between prothrombotic states and suicidality. Moreover, both protein S deficiency and antiphospholipid antibodies are associated with schizophrenia and there is an effect of warfarin on psychosis-free intervals. Studying the coagulation in the brain could open a new door in understanding and treating neurological and psychiatric disorders, and extensive research should be conducted in this field.

Keywords

inflammation - coagulation - thrombin - psychiatric disorders

Publikationsverlauf

Artikel online veröffentlicht:
23. Januar 2025

• References

• 1 Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15 (07) 254-259
• 2 Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34 (01) 43-62
• 3 Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011; 17 (5–6): 568-573
• 4 Chapman J. Coagulation in inflammatory diseases of the central nervous system. Semin Thromb Hemost 2013; 39 (08) 876-880
• 5 Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131 (04) 417-430
• 6 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2, Suppl): S26-S34
• 7 Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83 (03) 536-545
• 8 Cho A, McKelvey KJ, Lee A, Hudson AL. The intertwined fates of inflammation and coagulation in glioma. Mamm Genome 2018; 29 (11–12): 806-816
• 9 Mi Y, Qi G, Vitali F. et al. Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. Nat Metab 2023; 5 (03) 445-465
• 10 Kim H, Leng K, Park J. et al. Reactive astrocytes transduce inflammation in a blood-brain barrier model through a TNF-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin. Nat Commun 2022; 13 (01) 6581
• 11 Rothhammer V, Quintana FJ. Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol 2015; 37 (06) 625-638
• 12 Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 1998; 8 (02) 157-166
• 13 Nikcevich KM, Gordon KB, Tan L. et al. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol 1997; 158 (02) 614-621
• 14 Sun D, Coleclough C, Whitaker JN. Nonactivated astrocytes downregulate T cell receptor expression and reduce antigen-specific proliferation and cytokine production of myelin basic protein (MBP)-reactive T cells. J Neuroimmunol 1997; 78 (1–2): 69-78
• 15 Yang JF, Tao HQ, Liu YM. et al. Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice. Clin Exp Immunol 2012; 170 (03) 254-265
• 16 Lin CC, Lee IT, Wu WB. et al. Thrombin mediates migration of rat brain astrocytes via PLC, Ca²⁺, CaMKII, PKCα, and AP-1-dependent matrix metalloproteinase-9 expression. Mol Neurobiol 2013; 48 (03) 616-630
• 17 Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 2017; 35: 441-468
• 18 Han C, Xia X, Jiao S, Li G, Ran Q, Yao S. Tripartite motif containing protein 37 involves in thrombin stimulated BV-2 microglial cell apoptosis and interleukin 1β release. Biochem Biophys Res Commun 2019; 516 (04) 1252-1257
• 19 Ye X, Zuo D, Yu L. et al. ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia. Biochem Biophys Res Commun 2017; 485 (02) 499-505
• 20 Yang Y, Zhang M, Kang X. et al. Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice. Behav Brain Funct 2015; 11 (01) 30
• 21 Huang C, Ma R, Sun S. et al. JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J Neuroimmunol 2008; 204 (1–2): 118-125
• 22 Lee DY, Park KW, Jin BK. Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. Biochem Biophys Res Commun 2006; 346 (03) 727-738
• 23 Iannucci J, Renehan W, Grammas P. Thrombin, a mediator of coagulation, inflammation, and neurotoxicity at the neurovascular interface: implications for Alzheimer's disease. Front Neurosci 2020; 14: 762
• 24 Gofrit SG, Shavit-Stein E. The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases. Neural Regen Res 2019; 14 (12) 2043-2053
• 25 Kant R, Halder SK, Fernández JA, Griffin JH, Milner R. Activated protein C attenuates experimental autoimmune encephalomyelitis progression by enhancing vascular integrity and suppressing microglial activation. Front Neurosci 2020; 14: 333
• 26 Huuskonen MT, Wang Y, Nikolakopoulou AM. et al. Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. J Exp Med 2022; 219 (01) e20211372
• 27 Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006; 65 (01) 19-25
• 28 Deschepper CF, Bigornia V, Berens ME, Lapointe MC. Production of thrombin and antithrombin III by brain and astroglial cell cultures. Brain Res Mol Brain Res 1991; 11 (3–4): 355-358
• 29 Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991; 6 (04) 575-581
• 30 Shlobin NA, Har-Even M, Itsekson-Hayosh Z, Harnof S, Pick CG. Role of thrombin in central nervous system injury and disease. Biomolecules 2021; 11 (04) 562
• 31 Park GH, Ryu JR, Shin CY. et al. Evidence that protease-activated receptor-2 mediates trypsin-induced reversal of stellation in cultured rat astrocytes. Neurosci Res 2006; 54 (01) 15-23
• 32 De Luca C, Virtuoso A, Maggio N, Papa M. Neuro-coagulopathy: blood coagulation factors in central nervous system diseases. Int J Mol Sci 2017; 18 (10) 2128
• 33 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64 (06) 1057-1068
• 34 Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 1994; 91 (20) 9208-9212
• 35 Ishihara H, Connolly AJ, Zeng D. et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386 (6624): 502-506
• 36 Xu WF, Andersen H, Whitmore TE. et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998; 95 (12) 6642-6646
• 37 Suo Z, Wu M, Ameenuddin S. et al. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem 2002; 80 (04) 655-666
• 38 Ubl JJ, Vöhringer C, Reiser G. Co-existence of two types of [Ca2+]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells. Neuroscience 1998; 86 (02) 597-609
• 39 Wang KC, Koprivica V, Kim JA. et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002; 417 (6892): 941-944
• 40 Wang Y, Richter-Landsberg C, Reiser G. Expression of protease-activated receptors (PARs) in OLN-93 oligodendroglial cells and mechanism of PAR-1-induced calcium signaling. Neuroscience 2004; 126 (01) 69-82
• 41 Déry O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998; 274 (06) C1429-C1452
• 42 Peach CJ, Edgington-Mitchell LE, Bunnett NW, Schmidt BL. Protease-activated receptors in health and disease. Physiol Rev 2023; 103 (01) 717-785
• 43 Sokolova E, Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 2008; 100 (04) 576-581
• 44 Rohatgi T, Sedehizade F, Reymann KG, Reiser G. Protease-activated receptors in neuronal development, neurodegeneration, and neuroprotection: thrombin as signaling molecule in the brain. Neuroscientist 2004; 10 (06) 501-512
• 45 Noorbakhsh F, Vergnolle N, Hollenberg MD, Power C. Proteinase-activated receptors in the nervous system. Nat Rev Neurosci 2003; 4 (12) 981-990
• 46 Smith-Swintosky VL, Zimmer S, Fenton II JW, Mattson MP. Opposing actions of thrombin and protease nexin-1 on amyloid beta-peptide toxicity and on accumulation of peroxides and calcium in hippocampal neurons. J Neurochem 1995; 65 (03) 1415-1418
• 47 Perraud F, Besnard F, Sensenbrenner M, Labourdette G. Thrombin is a potent mitogen for rat astroblasts but not for oligodendroblasts and neuroblasts in primary culture. Int J Dev Neurosci 1987; 5 (03) 181-188
• 48 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3 (08) 1800-1814
• 49 Shavit E, Beilin O, Korczyn AD. et al. Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. Brain 2008; 131 (Pt 4): 1113-1122
• 50 Zhang Y, Guo H, Kwan H, Wang JW, Kosek J, Lu B. PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction. Neuron 2007; 53 (02) 201-215
• 51 Woods DF, Hough C, Peel D, Callaini G, Bryant PJ. Dlg protein is required for junction structure, cell polarity, and proliferation control in Drosophila epithelia. J Cell Biol 1996; 134 (06) 1469-1482
• 52 Gurwitz D, Cunningham DD. Thrombin modulates and reverses neuroblastoma neurite outgrowth. Proc Natl Acad Sci U S A 1988; 85 (10) 3440-3444
• 53 Suidan HS, Bouvier J, Schaerer E, Stone SR, Monard D, Tschopp J. Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes. Proc Natl Acad Sci U S A 1994; 91 (17) 8112-8116
• 54 Emilsson K, Wahlestedt C, Sun MK, Nystedt S, Owman C, Sundelin J. Vascular effects of proteinase-activated receptor 2 agonist peptide. J Vasc Res 1997; 34 (04) 267-272
• 55 Steinhoff M, Vergnolle N, Young SH. et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6 (02) 151-158
• 56 Lee PR, Johnson TP, Gnanapavan S. et al. Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β. J Neuroinflammation 2017; 14 (01) 131
• 57 Noorbakhsh F, Tsutsui S, Vergnolle N. et al. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 2006; 203 (02) 425-435
• 58 Rezaie AR. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost 2014; 112 (05) 876-882
• 59 Rajput PS, Lamb J, Kothari S. et al. Neuron-generated thrombin induces a protective astrocyte response via protease activated receptors. Glia 2020; 68 (02) 246-262
• 60 Itsekson-Hayosh Z, Shavit-Stein E, Katzav A. et al. Minimal traumatic brain injury in mice: protease-activated receptor 1 and thrombin-related changes. J Neurotrauma 2016; 33 (20) 1848-1854
• 61 Bushi D, Stein ES, Golderman V. et al. A linear temporal increase in thrombin activity and loss of its receptor in mouse brain following ischemic stroke. Front Neurol 2017; 8: 138
• 62 Esmon CT. The protein C pathway. Chest 2003; 124 (3, Suppl): 26S-32S
• 63 Thiyagarajan M, Fernández JA, Lane SM, Griffin JH, Zlokovic BV. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci 2008; 28 (48) 12788-12797
• 64 Wang J, Rao G, Ma Y, Zhang J, Shen J, Shi C. Neuroprotective effect of activated protein C on blood-brain barrier injury during focal cerebral ischemia/reperfusion. Dose Response 2020; 18 (02) 1559325820917288
• 65 Golderman V, Ben-Shimon M, Maggio N. et al. Factor VII, EPCR, aPC modulators: novel treatment for neuroinflammation. J Neuroinflammation 2022; 19 (01) 138
• 66 Davalos D, Ryu JK, Merlini M. et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012; 3: 1227
• 67 Adams RA, Bauer J, Flick MJ. et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204 (03) 571-582
• 68 Petersen MA, Ryu JK, Chang KJ. et al. Fibrinogen activates BMP signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage. Neuron 2017; 96 (05) 1003-1012.e7
• 69 Verbout NG, Yu X, Healy LD. et al. Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metab Brain Dis 2015; 30 (01) 57-65
• 70 Han MH, Hwang SI, Roy DB. et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451 (7182): 1076-1081
• 71 Beilin O, Karussis DM, Korczyn AD. et al. Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J Neurosci Res 2005; 79 (03) 351-359
• 72 De Meyer SF, Denorme F, Langhauser F, Geuss E, Fluri F, Kleinschnitz C. Thromboinflammation in stroke brain damage. Stroke 2016; 47 (04) 1165-1172
• 73 Petrovic-Djergovic D, Goonewardena SN, Pinsky DJ. Inflammatory disequilibrium in stroke. Circ Res 2016; 119 (01) 142-158
• 74 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114 (12) 2367-2374
• 75 Amara U, Rittirsch D, Flierl M. et al. Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632: 71-79
• 76 Anrather J, Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics 2016; 13 (04) 661-670
• 77 Bushi D, Chapman J, Katzav A. et al. Quantitative detection of thrombin activity in an ischemic stroke model. J Mol Neurosci 2013; 51 (03) 844-850
• 78 Bushi D, Ben Shimon M, Shavit Stein E, Chapman J, Maggio N, Tanne D. Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus. J Neurochem 2015; 135 (06) 1140-1148
• 79 Bushi D, Chapman J, Wohl A, Stein ES, Feingold E, Tanne D. Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke. J Neurosci Res 2018; 96 (08) 1406-1411
• 80 Stein ES, Itsekson-Hayosh Z, Aronovich A. et al. Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke. Sci Rep 2015; 5: 7912
• 81 Krenzlin H, Lorenz V, Danckwardt S, Kempski O, Alessandri B. The importance of thrombin in cerebral injury and disease. Int J Mol Sci 2016; 17 (01) 84
• 82 Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis 2006; 9 (01) 51-58
• 83 Alabanza LM, Bynoe MS. Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. J Neuroimmunol 2012; 245 (1–2): 48-55
• 84 Brailoiu E, Shipsky MM, Yan G, Abood ME, Brailoiu GC. Mechanisms of modulation of brain microvascular endothelial cells function by thrombin. Brain Res 2017; 1657: 167-175
• 85 Birukova AA, Birukov KG, Smurova K. et al. Novel role of microtubules in thrombin-induced endothelial barrier dysfunction. FASEB J 2004; 18 (15) 1879-1890
• 86 Liu DZ, Ander BP, Xu H. et al. Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. Ann Neurol 2010; 67 (04) 526-533
• 87 Rao HV, Thirumangalakudi L, Desmond P, Grammas P. Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons. J Neurochem 2007; 101 (02) 498-505
• 88 Smirnova IV, Vamos S, Wiegmann T, Citron BA, Arnold PM, Festoff BW. Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons. J Mol Neurosci 1998; 10 (01) 31-44
• 89 Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47 (13) 2161-2169
• 90 Dzik S. Complement and coagulation: cross talk through time. Transfus Med Rev 2019; 33 (04) 199-206
• 91 Amara U, Flierl MA, Rittirsch D. et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185 (09) 5628-5636
• 92 Huber-Lang M, Sarma JV, Zetoune FS. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (06) 682-687
• 93 Hertle E, van Greevenbroek MM, Arts IC. et al. Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease. The CODAM study. Thromb Haemost 2014; 111 (06) 1102-1111
• 94 Barrett CD, Hsu AT, Ellson CD. et al. Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy. Clin Exp Immunol 2018; 194 (01) 103-117
• 95 Dumais A, Lesage AD, Alda M. et al. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry 2005; 162 (11) 2116-2124
• 96 Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999; 55 (2–3): 171-178
• 97 Yang Y, Chen J, Liu C. et al. The extrinsic coagulation pathway: a biomarker for suicidal behavior in major depressive disorder. Sci Rep 2016; 6: 32882
• 98 Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S147-S152
• 99 Doulalas AD, Rallidis LS, Gialernios T. et al. Association of depressive symptoms with coagulation factors in young healthy individuals. Atherosclerosis 2006; 186 (01) 121-125
• 100 Duca L, Roman N, Teodorescu A, Ifteni P. Association between inflammation and thrombotic pathway link with pathogenesis of depression and anxiety in SLE patients. Biomolecules 2023; 13 (03) 567
• 101 Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations. Semin Thromb Hemost 2013; 39 (08) 935-942
• 102 Katzav A, Shoenfeld Y, Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010; 38 (2–3): 196-200
• 103 Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res 2015; 135 (Suppl. 01) S56-S59
• 104 Katzav A, Menachem A, Maggio N, Pollak L, Pick CG, Chapman J. IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome. J Autoimmun 2014; 55: 86-93
• 105 Hoirisch-Clapauch S, Amaral OB, Mezzasalma MAU, Panizzutti R, Nardi AE. Dysfunction in the coagulation system and schizophrenia. Transl Psychiatry 2016; 6 (01) e704
• 106 Hoirisch-Clapauch S, Nardi AE. Markers of low activity of tissue plasminogen activator/plasmin are prevalent in schizophrenia patients. Schizophr Res 2014; 159 (01) 118-123
• 107 Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: should psychosis be addressed as plasminogen activator imbalance?. Med Hypotheses 2013; 80 (02) 137-141